Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
mindeudesivir hydrobromide + clarithromycin
- Development stage
- Unknown
- Lead developer
- Junshi Biosciences
- Modality
- Small Molecules
- Administration
- Oral, Intravenous
01
Overview
Mindeudesivir hydrobromide (VV116) is an oral antiviral agent structurally related to remdesivir and developed as a deuterated analog for the treatment of COVID-19. It retains the antiviral activity of remdesivir against SARS-CoV-2 and is notable for being one of the first domestically produced deuterium-modified antivirals targeting COVID-19[8]. Clarithromycin is a semi-synthetic macrolide antibiotic used to treat various bacterial infections including respiratory tract infections, skin infections, and as part of combination therapy for Helicobacter pylori eradication. It acts by binding to domain V of 23S rRNA in the 50S subunit of bacterial ribosomes, inhibiting protein synthesis[1][3][4]. The combination described here does not represent a standard or approved fixed-dose product but rather two separate agents with distinct mechanisms—one antiviral (mindeudesivir hydrobromide) and one antibacterial (clarithromycin).
- Brand names
- BiaxinBiaxin XL
- Other names
- mindeudesivir hydrobromideVV116VV-116VV 116clarithromycin
02
Targets
RdRp (Coronavirus RNA-dependent RNA polymerase)Bacterial 50S ribosomal subunit
Beyond the preview
Go deeper on mindeudesivir hydrobromide + clarithromycin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on mindeudesivir hydrobromide + clarithromycin.